<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02447653</url>
  </required_header>
  <id_info>
    <org_study_id>BMETAU09</org_study_id>
    <nct_id>NCT02447653</nct_id>
  </id_info>
  <brief_title>Hydroxyapatite (HA) Coating Versus Plasma Porous Spray (PPS) in Press-fit Acetabular Components Early Outcomes With DEXA</brief_title>
  <official_title>A Randomised Controlled Study Comparing Hydroxyapatite (HA) Coating Versus Plasma Porous Spray in Press-fit Acetabular Components Early Outcomes With Dual Energy X-ray Absorptiometry (DEXA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study design comprises a randomized trial of patients undergoing primary total hip
      arthroplasty using the G7 acetabular system and Taperloc Complete stem comparing regular
      plasma porous spray with HA coating using Bonemaster (BM) in an uncemented cup. DEXA scanning
      will be used to measure periprosthetic bone mineral density. Clinical evaluations will be
      conducted .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design comprises a randomized trial of patients undergoing primary total hip
      arthroplasty using the G7 acetabular system and Taperloc Complete stem comparing regular
      plasma porous spray with HA coating using Bonemaster (BM) in an uncemented cup. DEXA scanning
      will be used to measure periprosthetic bone mineral density preoperatively and
      post-operatively at 6 weeks, 12 weeks, 26 weeks, and 12 months for both the treated and
      contralateral hip joint. Clinical evaluations will be conducted preoperatively, and
      postoperatively at 6, 12, 26 weeks, 12 months and 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 15, 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Remodelling (DEXA analysis)</measure>
    <time_frame>12 months</time_frame>
    <description>DEXA analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical (Harris Hip Score)</measure>
    <time_frame>24 months</time_frame>
    <description>Harris Hip Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical (Oxford Hip Score)</measure>
    <time_frame>24 months</time_frame>
    <description>Oxford Hip Score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Hydroxyapatite Coating</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G7 HA Acetabular component will be implanted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plasma Porous Spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>G7 PPS Acetabular component will be implanted</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>G7 HA Acetabular Component</intervention_name>
    <description>G7 HA Acetabular Component</description>
    <arm_group_label>Hydroxyapatite Coating</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>G7 PPS Acetabular Component</intervention_name>
    <description>G7 PPS Acetabular Component</description>
    <arm_group_label>Plasma Porous Spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with osteoarthritis who are candidates for a primary total hip replacement
             with uncemented acetabular and femoral components as determined by the surgeon.

          2. Male and non-pregnant female patient aged 18 to 70.

          3. Patients who understand the conditions of the study and are willing to participate for
             the length of the prescribed follow-up.

        Exclusion Criteria:

          1. Patients requiring total hip replacement surgery for a fresh hip fracture.

          2. Patients with inflammatory arthritis

          3. Patients with metabolic bone disease or taking drugs that affect bone turnover. 4
             .Patients requiring revision surgery of a previously implanted total hip replacement
             system or patients requiring a conversion surgery from a previous fracture fixation or
             hip fusion.

        5. Patients with presence of malignancy in the area of the involved hip joint. 6. Patients
        who, as judged by the surgeon, are mentally incompetent or are reasonably unlikely to be
        compliant with the prescribed postoperative routine and the follow-up evaluation schedule.

        7. Patients with other concurrent illnesses that are likely to affect their outcome such as
        sickle cell anaemia, systemic lupus erythematosus or renal disease requiring dialysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gold Coast Centre for Bone and Joint Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Greenslopes Private Hospital</name>
      <address>
        <city>Greenslopes</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 8, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

